PYC Therapeutics concluded dosing for the fourth cohort in its single ascending dose trial for RP11, a blinding eye disease in children.

The milestone advances the development of the first precision medicine for RP11, with plans to initiate an open-label multiple ascending dose study in the second quarter.

The multiple ascending dose study aims to assess safety and dosage efficacy based on insights from the single ascending dose trial.

The completion of both trials is crucial for progressing to a registrational trial in 2025.